drugset
drugset / Trial / NCT01408043

Etoposide, Filgrastim, and Plerixafor in Improving Stem Cell Mobilization in Treating Patients With Non-Hodgkin Lymphoma

NCT01408043 ↗

Terminated 25 enrolled Case Comprehensive Cancer Center National Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment

Summary

This clinical trial studies etoposide, filgrastim and plerixafor in improving stem cell mobilization in patients with non-Hodgkin lymphoma. Giving colony-stimulating factors, such as filgrastim, and plerixafor and etoposide together helps stem cells move from the patient's bone marrow to the blood so they can be collected and stored.

Timeline

Start
2011-10
Primary completion
2016-05
Completion
2016-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Plerixafor Small molecule — Subcutaneous
Background Etoposide Small molecule — Intravenous
Background filgrastim Protein / enzyme biologic — Subcutaneous

Indications

Burkitt lymphoma MALT lymphoma T-cell large granular lymphocyte leukemia Waldenstrom macroglobulinemia adult T-cell leukemia/lymphoma adult acute lymphoblastic leukemia anaplastic large cell lymphoma angioimmunoblastic T-cell lymphoma chronic lymphocytic leukemia/small lymphocytic lymphoma extranodal nasal NK/T cell lymphoma grade III lymphomatoid granulomatosis hairy cell leukemia hepatosplenic T-cell lymphoma large-cell immunoblastic lymphoma mantle cell lymphoma mycosis fungoides and variants nodal marginal zone B-cell lymphoma peripheral T-cell lymphoma, not otherwise specified primary cutaneous B-cell lymphoma small intestine lymphoma splenic marginal zone lymphoma testicular lymphoma